Hemab Therapeutics (COAG) Stock Forecast & Price Target

COAG$40.86+1.48 +3.76%
BiotechnologyValue StockGrowth Stock
Compare
Market cap$1.91BEnterprise value$1.39BRevenue (TTM)$0Market position—

Score

70
Bullish
Value
66
Quality
50
Growth
95

Hemab Therapeutics Holdings, Inc. Common Stock price target

COAG
Low$36.00
Average$51.40
High$64.00
Upside vs current price+25.8%

The average target of $51.40 is +25.8% versus the current COAG price of $40.86.

Hemab Therapeutics Holdings, Inc. Common Stock analyst ratings

RatingAnalysts
Strong buy0
Buy3
Hold0
Sell0
Strong sell0
ConsensusBuy

3 analysts cover COAG.

Hemab Therapeutics Holdings, Inc. Common Stock EPS and revenue estimates

COAG shows the next fiscal years with at least three analysts: 2026 EPS $-3.05, 2027 EPS $-2.47. A thinner year is left off this table.

Fiscal yearEPS estimateRevenue estimate
2026$-3.05—
2027$-2.47—

Is Hemab Therapeutics Holdings, Inc. Common Stock a buy or sell?

Of the 3 analysts covering Hemab Therapeutics Holdings, Inc. Common Stock, 3 rate it a buy (0 strong buy and 3 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The COAG consensus label is Buy, beside 3 buy-side ratings and 0 sell-side ratings.

The average target of $51.40 implies +25.8% versus the current price of $40.86.

Those 3 ratings on COAG are a headcount, and the label on file is Buy.

Reading the Hemab Therapeutics Holdings, Inc. Common Stock forecast

The COAG target range is wide: $36.00 at the low end, $51.40 in the middle, and $64.00 at the top.

Set next to the $40.86 COAG quote, that average is +25.8%.

Ratings on the Hemab Therapeutics Holdings, Inc. Common Stock cluster: 3 of 3 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.

The COAG EPS path from 2026 ($-3.05) to 2027 ($-2.47) is rising.

Only 3 analysts cover COAG, so the average rests on a short list.

Hemab Therapeutics Holdings, Inc. Common Stock forecast questions

What is the COAG price target?

The published range for COAG is $36.00 to $64.00, with an average of $51.40. That average is +25.8% versus the current price of $40.86.

Is Hemab Therapeutics Holdings, Inc. Common Stock a buy or sell?

Of the 3 analysts covering Hemab Therapeutics Holdings, Inc. Common Stock, 3 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the COAG headcount is 3 buy, 0 hold, and 0 sell.

What is the EPS estimate for Hemab Therapeutics Holdings, Inc. Common Stock?

Analyst EPS estimates for Hemab Therapeutics Holdings, Inc. Common Stock: 2026 $-3.05, 2027 $-2.47.

What is the revenue estimate for Hemab Therapeutics Holdings, Inc. Common Stock?

No revenue estimate with at least 3 analysts is on file for Hemab Therapeutics Holdings, Inc. Common Stock.

How many analysts cover COAG?

3 analysts cover COAG. Their consensus on COAG is Buy, across those 3.

COAG price $40.86 +1.48 +3.76%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener